As seen previously with liraglutide, the most frequently reported side effects were gastrointestinal, but dose-escalation helps to mitigate these
Your wallet will thank you
Developed by Eli Lilly, retatrutide simultaneously targets GLP-1, GIP, and glucagon receptors, setting it apart from existing licensed treatments such as semaglutide and tirzepatide
This makes it a gentler option for those who want appetite support without the need for injections
The dual agonist action on both GIP and GLP-1 receptors may produce different gastrointestinal effects compared to single GLP-1 agonists, though comparative data specifically regarding reflux incidence remain limited
Elle aide augmenter la capacit du corps brler les graisses, ce qui peut acclrer la perte de poids